Checkpoint Therapeutics (CKPT) Upgraded to Buy at Zacks Investment Research

Zacks Investment Research upgraded shares of Checkpoint Therapeutics (NASDAQ:CKPT) from a hold rating to a buy rating in a report issued on Thursday morning. They currently have $4.00 price objective on the stock.

According to Zacks, “Checkpoint Therapeutics, Inc. is a clinical stage, immuno oncology biopharmaceutical. It focused on the acquisition, development and commercialization of non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Checkpoint Therapeutics, Inc. is headquartered in New York City. “

Separately, HC Wainwright assumed coverage on Checkpoint Therapeutics in a research note on Friday, December 8th. They set a buy rating and a $11.00 price target for the company.

Checkpoint Therapeutics (NASDAQ CKPT) traded down $0.37 during mid-day trading on Thursday, reaching $3.24. The company’s stock had a trading volume of 102,600 shares, compared to its average volume of 91,767. Checkpoint Therapeutics has a fifty-two week low of $3.20 and a fifty-two week high of $15.00.

WARNING: “Checkpoint Therapeutics (CKPT) Upgraded to Buy at Zacks Investment Research” was originally reported by Ticker Report and is the property of of Ticker Report. If you are viewing this piece of content on another domain, it was copied illegally and republished in violation of U.S. & international copyright laws. The legal version of this piece of content can be accessed at https://www.tickerreport.com/banking-finance/3127292/checkpoint-therapeutics-ckpt-upgraded-to-buy-at-zacks-investment-research.html.

Checkpoint Therapeutics Company Profile

Checkpoint Therapeutics, Inc is an immuno-oncology biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. The Company is engaged in developing a portfolio of human immuno-oncology targeted antibodies.

Receive News & Ratings for Checkpoint Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Checkpoint Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


© 2006-2018 Ticker Report. Google+.